André Moreira de Assis1, Airton Mota Moreira2, Vanessa Cristina de Paula Rodrigues2, Eduardo Muracca Yoshinaga3, Alberto Azoubel Antunes3, Sardis Honoria Harward4, Miguel Srougi3, Francisco Cesar Carnevale2. 1. Interventional Radiology and Endovascular Surgery Department, University of Sao Paulo Medical School, Dr. Enéas de Carvalho Aguiar Avenue, 255, Cerqueira César, 05403000 São Paulo, Brazil. Electronic address: andre.maa@gmail.com. 2. Interventional Radiology and Endovascular Surgery Department, University of Sao Paulo Medical School, Dr. Enéas de Carvalho Aguiar Avenue, 255, Cerqueira César, 05403000 São Paulo, Brazil. 3. Radiology Institute, and Urology Department, University of Sao Paulo Medical School, Dr. Enéas de Carvalho Aguiar Avenue, 255, Cerqueira César, 05403000 São Paulo, Brazil. 4. The Dartmouth Center for Health Care Delivery Science, Hanover, New Hampshire.
Abstract
PURPOSE: To describe the safety and efficacy of prostatic artery embolization (PAE) with spherical microparticles to treat lower urinary tract symptoms associated with benign prostatic hyperplasia in patients with prostate volume > 90 g. MATERIALS AND METHODS: This prospective, single-center, single-arm study was conducted in 35 patients with prostate volumes ranging from 90-252 g. Mean patient age was 64.8 years (range, 53-77 y). Magnetic resonance imaging, uroflowmetry, and the International Prostate Symptom Score (IPSS) were used to assess clinical and functional outcomes. RESULTS: Mean prostate size decreased significantly from 135.1 g before PAE to 91.9 g at 3 months of follow-up (P < .0001). Mean IPSS and quality-of-life index improved from 18.3 to 2.7 and 4.8 to 0.9 (P < .0001 for both), respectively. A significant negative correlation was observed between prostate-specific antigen at 24 hours after PAE and IPSS 3 months after PAE (P = .0057). CONCLUSIONS: PAE is a safe and effective treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia in patients with prostate volume > 90 g. Excessively elevated prostate-specific antigen within 24 hours of PAE is associated with lower symptom burden in short-term follow-up.
PURPOSE: To describe the safety and efficacy of prostatic artery embolization (PAE) with spherical microparticles to treat lower urinary tract symptoms associated with benign prostatic hyperplasia in patients with prostate volume > 90 g. MATERIALS AND METHODS: This prospective, single-center, single-arm study was conducted in 35 patients with prostate volumes ranging from 90-252 g. Mean patient age was 64.8 years (range, 53-77 y). Magnetic resonance imaging, uroflowmetry, and the International Prostate Symptom Score (IPSS) were used to assess clinical and functional outcomes. RESULTS: Mean prostate size decreased significantly from 135.1 g before PAE to 91.9 g at 3 months of follow-up (P < .0001). Mean IPSS and quality-of-life index improved from 18.3 to 2.7 and 4.8 to 0.9 (P < .0001 for both), respectively. A significant negative correlation was observed between prostate-specific antigen at 24 hours after PAE and IPSS 3 months after PAE (P = .0057). CONCLUSIONS:PAE is a safe and effective treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia in patients with prostate volume > 90 g. Excessively elevated prostate-specific antigen within 24 hours of PAE is associated with lower symptom burden in short-term follow-up.
Authors: Souhil Lebdai; Nicolas Barry Delongchamps; Marc Sapoval; Grégoire Robert; Gregory Amouyal; Nicolas Thiounn; Gilles Karsenty; Alain Ruffion; Alexandre de La Taille; Aurélien Descazeaud; Romain Mathieu Journal: World J Urol Date: 2015-08-15 Impact factor: 4.226
Authors: Mario Petrillo; Filippo Pesapane; Enrico Maria Fumarola; Ilaria Emili; Marzia Acquasanta; Francesca Patella; Salvatore Alessio Angileri; Umberto G Rossi; Igor Piacentini; Antonio Maria Granata; Anna Maria Ierardi; Gianpaolo Carrafiello Journal: Gland Surg Date: 2018-04